$999.00
Background：PD-1/VEGF Bispesific Antibody is a novel cancer immunotherapy drug that can target both PD-1 and VEGF. It blocks the interaction between PD-1 and PD-L1/PD-L2. The bispecific antibody can specifically bind to VEGFA and PD-1, selectively relieve the immune suppression caused by VEGFA and PD-1 in the body, and inhibit tumor-induced angiogenesis.
| Target | VEGF&PD1 |
| Reactivity | |
| Applications | Flow cytometry |
| MW(Calculated) | |
| MW(Observed) | |
| Host Species | Human |
| Isotype | IgG1, |
| Conjugate/Modification | Unconjugated |
| Modification | |
| Recommended Dilution Ratio | |
| Formulation Buffer | 20 mM Histidine, 100 mM NaCl, pH 6.0 |
| Source | |
| Purification | |
| Purity | > 95% as determined by SDS-PAGE |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -162℃ long term.Avoid repeated freeze-thaw. |
| Concentration | |
| Clonality | |
| Clone Number | Ivonescimab |
| Immunogen | |
| Sequence | |
| Specificity | |
| Gene Name | |
| Protein Name | |
| Other Name | VEGF: VPF; MVCD1; L-VEGFPD1: CD279 |
| Species | |
| Gene ID | |
| Uniprot | |
| Species.1 | |
| Gene ID.1 | |
| Uniprot.1 | |
| Species.2 | |
| Gene ID.2 | |
| Uniprot.2 | |
| Organism-4 | |
| GeneID-4 | |
| SwissProt-4 | |
| Cellular Localization | |
| Tissue Expression | |
| Signaling_pathway | |
| Research Areas | |
| Function | |
| RRID |
